Prostate Cancer: A Contemporary Approach to Treatment and Outcomes.

Prostate Cancer: A Contemporary Approach to Treatment and Outcomes. Med Clin North Am. 2018 Mar;102(2):215-229 Authors: Weiner AB, Kundu SD Abstract Given the high incidence of prostate cancer and the need for shared decision-making before screening, it is imperative that primary care providers understand treatment options and treatment adverse effects. In this review article, the treatment options for the localized and metastatic prostate cancer are discussed, including the different modalities and their indications, adverse effects, oncologic outcomes, posttreatment monitoring, and potential treatment options following cancer recurrence. PMID: 29406054 [PubMed - in process]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Med Clin North Am Source Type: research

Related Links:

Condition:   Low Risk Prostate Cancer Intervention:   Drug: TOOKAD VTP Sponsors:   Steba Biotech S.A.;   International Drug Development Institute;   PrimeVigilance LTD Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Initial concerns that finasteride could increase risk of prostate cancer death have been found to be unwarranted in a long-term follow-up study.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research
CONCLUSION: MRI-TRUS guided prostate biopsy improves the detection of PCa, but systematic biopsy is still essential. In selected cases (PIRADS 5), contralateral lobe systematic biopsy can safely be avoided. Pre-biopsy mpMRI might reduce the number of biopsy sessions in patients with anterior and transitional lesions. PMID: 30779829 [PubMed - in process]
Source: Medical Ultrasonography - Category: Radiology Tags: Med Ultrason Source Type: research
The results of the double-blind, phase III trial were presented at the 2019 ASCO Genitourinary Cancers Symposium.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
CONCLUSIONS: This study demonstrated that miR-492 was over-expressed in PCa and exerted tumor-promoting function in PCa cells via repressing SOCS2 expression. This might provide a new sight for future accurate therapy for PCa. PMID: 30779065 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Hope et al.1 report on the impact of pretreatment 68Ga-PSMA-PET/CT or PET/MRI in the management of 45 patients with high-risk prostate cancer (PCA). Results of PSMA-PET/CTs were compared to the findings of CT scans and skeletal scintigraphy. Based on their data, PSMA-PET imaging resulted in changes of radiation therapy (RT) dose and volumes in 47% of the patients due to newly diagnosed N1/M1a disease. RT changes resulted in the extension of clinical target volume (CTV) covering the small pelvis and even the retroperitoneum or a RT boost to avid lymph nodes.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
ConclusionssRP was safe, feasible, and effective using either an open or robot-assisted approach, in experienced hands. Age, preoperative clinical stage, NS procedure, and pathological GS were linked with BCR after sRP.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
ConclusionsAbsolute quantitative223Ra SPECT imaging appears feasible once the dimension of the target is determined. Further evaluation should be needed to apply the calibration factor-based quantitation to clinical223Ra SPECT/CT imaging. This will open the possibility for patient-specific223Ra treatment planning and therapeutic outcome prediction in patients.
Source: EJNMMI Research - Category: Radiology Source Type: research
Expanding genetic testing beyond current guidelines could better stratify prostate cancer patients for the presence of pathogenic variants and improve their medical management, researchers say.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news
The combination of ipilimumab with nivolumab shows activity in advanced disease.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Primary Care | Prostate Cancer